DPP-4 inhibitors in modern algorithms for the management of type 2 diabetes mellitus: focus on early combined pathogenetic therapy
https://doi.org/10.62751/2713-0177-2024-5-3-03
Abstract
The modern management strategy for patients with type 2 diabetes mellitus is based on the general management of risk factors, taking into account a personalized approach to each patient. Early combined hypoglycemic therapy is a priority in achieving long-term glycemic control. The leading place in all current recommendations for the management of type 2 diabetes mellitus is occupied by drugs of the DPP- 4 inhibitor class. The combination of DPP-4 inhibitors with metformin can help preserve insulin-producing function and improve glycemic control, and, accordingly, slow the progression of type 2 diabetes mellitus and its complications. The drug gozogliptin (Saterex®) is the first original gliptin, the full production cycle of which in Russia. Gozogliptin can be recommended for patients with the onset of type 2 diabetes mellitus both in combination with metformin and in monotherapy.
About the Authors
T. Yu. Demidova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Tatiana Yu. Demidova – D. Sci. (Med.), Prof.
Moscow
F. O. Ushanova
Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Fatima O. Ushanova – C. Sci. (Med.)
Moscow
References
1. World Health Organization. Diabetes. In: World Health Organization [Internet]. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes.
2. Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, Malanda B. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018 Apr;138:271-281. doi: 10.1016/j.diabres.2018.02.023.
3. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2022 Jan;183:109119. doi: 10.1016/j.diabres.2021.109119.
4. Дедов И.И., Шестакова М.В., Викулова О.К., Железнякова А.В., Исаков М.А., Сазонова Д.В., Мокрышева Н.Г. Сахарный диабет в Российской Федерации: динамика эпидемиологических показателей по данным Федерального регистра сахарного диабета за период 2010 – 2022 гг. Сахарный диабет. 2023;26(2):104-123. https://doi.org/10.14341/DM13035.
5. Kalra S, Bhattacharya S, Dhingra A, Das S, Kapoor N, Shaikh S, et al. Expert Consensus on Dipeptidyl Peptidase-4 Inhibitor-Based Therapies in the Modern Era of Type 2 Diabetes Mellitus Management in India. Cureus. 2024 Jun 5;16(6):e61766. doi: 10.7759/cureus.61766.
6. Williams DM, Jones H, Stephens JW. Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations. Diabetes Metab Syndr Obes. 2022 Feb 4;15:281-295. doi: 10.2147/DMSO.S331654.
7. Grant RW, Wexler DJ. Personalized medicine in Type 2 diabetes: what does the future hold? Diabetes Manag (Lond). 2012 May;2(3):199-204. doi: 10.2217/dmt.12.15.
8. Алгоритмы специализированной медицинской помощи больным сахарным диабетом / Под редакцией И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. – 11-й выпуск. – М.; 2023. doi: https://doi.org/10.14341/DM13042.
9. Florentin M, Kostapanos MS, Papazafiropoulou AK. Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatment. World J Diabetes. 2022 Feb 15;13(2):85-96. doi: 10.4239/wjd.v13.i2.85.
10. Викулова О.К., Железнякова А.В., Исаков М.А. и др. Структура сахароснижающей терапии у пациентов с сахарным диабетом 2 типа в Российской Федерации в 2017–2021 гг. В кн.: Сборник тезисов IX (XXVIII) Национального диабетологического конгресса с международным участием «Сахарный диабет и ожирение — неинфекционные междисциплинарные пандемии XXI века», 05–08 сентября 2022 года. М.; 2022.
11. Клинические рекомендации «Сахарный диабет 2 типа у взрослых». Режим доступа: https://cr.minzdrav.gov.ru/recomend/290_2.
12. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. American Diabetes Association. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2023. Diabetes Care. 2023 Jan 1;46(Suppl 1): S140-S157. doi: 10.2337/dc23-S009.
13. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2024. Diabetes Care. 2024 Jan 1;47(Suppl 1): S158-S178. doi: 10.2337/dc24-S009.
14. Singh AK, Singh R. Relook at DPP-4 inhibitors in the era of SGLT-2 inhibitors. World J Diabetes. 2022 Jun 15;13(6):466-470. doi: 10.4239/wjd.v13.i6.466.
15. Del Prato S, Rosenstock J, Garcia-Sanchez R, Iqbal N, Hansen L, Johnsson E, Chen H, Mathieu C. Safety and tolerability of dapagliflozin, saxagliptin and metformin in combination: Post-hoc analysis of concomitant add-on vs sequential add-on to metformin and of triple vs dual therapy with metformin. Diabetes Obes Metab. 2018;20:1542–1546.
16. Holst J.J., Deacon C.F. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes. 1998;47:1663–1670. doi: 10.2337/diabetes.47.11.1663.
17. Ahren B. Dipeptidyl peptidase-4 inhibitors: Clinical data and clinical implications. Diabetes Care. 2007;30:1344–1350. doi: 10.2337/dc07-0233.
18. Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res. 2012 Apr;9(2):109-16. doi: 10.1177/1479164111436236.
19. Matthews D.R., Paldánius P.M., Proot P. et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529. DOI: 10.1016/S0140-6736(19)32131-2.
20. Rosenstock J., Perkovic V., Johansen O.E. et al. CARMELINA Investigators. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69–79. DOI: 10.1001/jama.2018.18269.
21. McGuire D.K., Alexander J.H., Johansen O.E. et al. CARMELINA Investigators. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. Circulation. 2019;139(3):351–361. DOI: 10.1161/CIRCULATIONAHA.118.038352.
22. Rosenstock J., Kahn S.E., Johansen O.E., Zinman B., Espeland M.A., Woerle H.J. et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial // JAMA. 2019. Vol. 322, N 12. P. 1155-1166. DOI: https://doi.org/10.1001/jama.2019.13772
23. Zannad F., Cannon C.P., Cushman W.C.B. et al.; EXAMINE Investigators. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076. DOI: 10.1016/S0140-6736(14)62225-X.
24. Green J.B., Bethel M.A., Armstrong P.W. et al.; TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232–242. DOI: 10.1056/NEJMoa1501352.
25. Chikata Y., Iwata H., Miyosawa K., Koike T., Yasuda H., Funamizu T., Doi S., Endo H., Wada H., Naito R., et al. Dipeptidyl peptidase-4 inhibitors reduced long-term cardiovascular risk in diabetic patients after percutaneous coronary intervention via insulin-like growth factor-1 axis. Sci. Rep. 2022;12:5129. doi: 10.1038/s41598-022-09059-2.
26. Scirica B.M., Braunwald E., Raz I. et al.; SAVOR-TIMI 53 Steering Committee and Investigators. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized triaL. Circulation. 2014;130:1579–1588. doi: 10.1161/CIRCULATIONAHA.114.010389.
27. Samson SL, Vellanki P, Blonde L, Christofides EA, Galindo RJ, Hirsch IB, et al. American Association of Clinical Endocrinology Consensus Statement: Comprehensive Type 2 Diabetes Management Algorithm - 2023 Update. Endocr Pract. 2023 May;29(5):305-340. doi: 10.1016/j.eprac.2023.02.001.
28. Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes. Diabetes Care. 2018 Jan;41(1):69-78. doi: 10.2337/dc17-1414.
29. Галстян К.О., Недосугова Л.В., Петунина Н.А., Трахтенберг Ю.А., Востокова Н.В., Караваева О.В., Часовская Т.Е. Первый отечественный ингибитор ДПП-4 госоглиптин в сравнении с вилдаглиптином при лечении пациентов с сахарным диабетом 2 типа. Сахарный диабет. 2016;19(1):89-96. https://doi.org/10.14341/DM7233
30. Черникова Н.А., Аметов А.С. Опыт применения российского ингибитора дипептидилпептидазы-4 гозоглиптина. Результаты исследования ОНИКС // Эндокринология: новости, мнения, обучение. 2021. Т. 10, № 1. C. 62-69. DOI: https://doi.org/10.33029/2304-9529-2021-10-1-62-69
31. Шестакова М.В., Бирюкова Е.В. Практическое применение российского ингибитора ДПП-4 гозоглиптина в масштабном наблюдательном исследовании «Палитра». Сахарный диабет. 2024;27(4):347-356. https://doi.org/10.14341/DM13193
Review
For citations:
Demidova T.Yu., Ushanova F.O. DPP-4 inhibitors in modern algorithms for the management of type 2 diabetes mellitus: focus on early combined pathogenetic therapy. FOCUS. Endocrinology. 2024;5(3):22-29. (In Russ.) https://doi.org/10.62751/2713-0177-2024-5-3-03
Views:
100
Email this article 